PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Spesolimab - Pustular psoriasis
PAD Profile : Spesolimab - Pustular psoriasis
Brand Names Include :
Spevigo
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
- Wet age-related macular degeneration
- Lambert-Eaton myasthenic syndrome (LEMS)
- Respiratory distress in preterm neonates
- Pain
- Diabetic retinopathy
- Osteoarthritis
- Respiratory distress in preterm neonates
- Hepatic encephalopathy
- Travellers diarrhoea
- Penile rehabilitation
- Erectile dysfunction
- Cytomegalovirus
- Hyperuricaemia and Gout
- Vitreomacular traction
- Retinal Vein Occlusion
- Peripheral arterial disease
- Dysphagia
- Diabetic macular oedema
- Diarrhoea
- Haemorrhoids
- Heart failure
- Oedema
- Lipid modification
- Haemophilia
- Cataracts
- Branch retinal vein occlusion
- Low sexual desire in menopausal women
- Hypertension
- Hypertension
- Hypertension
- Bacterial infection
- Inflammatory bowel disease
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Myopic choroidal neovascularisation
- Cystic fibrosis
- Fungal infection
- Duchenne muscular dystrophy
- Cystic fibrosis
- Hepatitis C
- Tuberculosis
- Hepatitis C
- Multiple sclerosis
- Tuberculosis
- Hepatitis C
- Hepatitis C
- Hepatitis C
- Haemophilia
- Cystic fibrosis
- Hepatitis C
- Systemic Lupus Erythematosus
- Hepatitis C
- Inclusion body myositis
- Cytomegalovirus
- Asthma
- Haemophilia
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Hepatitis C
- Haemophilia
- Systemic Lupus Erythematosus
- Haemophilia
- Haemophilia
- Haemophilia
- Haemophilia
- Multiple sclerosis
- Hepatitis B
- Haemophilia
- Short bowel syndrome
- Haemophilia
- Any paediatric use
- von Willebrand deficiency
- Haemophilia
- Haemophilia
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Mental Health disorders
- Mental Health disorders
- Inflammatory bowel disease
- Acne
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Non-acne dermatological indications
- Anticoagulation reversal
- Restless Leg Syndrome
- von Willebrand deficiency
- Smoking cessation
- Immune thrombocytopenia
- Wet age-related macular degeneration
- Bacterial skin and skin structure infections
- Cystic fibrosis
- Narcolepsy
- Bacterial lung infection (non-cystic fibrosis)
- Lipid modification
- Menopausal disorders
- All
- Raynaud's Phenomenon
- Atopic dermatitis
- Psoriasis
- Clostridioides difficile
- Hereditary angiodema
- Covid-19
- Covid-19
- Covid-19
- Peanut allergy in children and young people
- Inflammatory bowel disease
- Growth failure - children
- Inflammatory bowel disease
- Diabetic macular oedema
- Wet age-related macular degeneration
- Diabetic macular oedema
- Migraine (prevention)
- Urinary incontinence
- Immune thrombocytopenia
- Glaucoma / ocular hypertension
- Dry eyes
- Cancer
- Diarrhoea
- Inflammatory bowel disease
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pain
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
- Erectile dysfunction
- Parkinson's disease
- Myasthenia gravis
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Bacterial infection
- Tuberculosis
- Tuberculosis
- Tuberculosis
- Covid-19
- Inflammatory bowel disease
- Rehydration in short bowel syndrome
- Minor digestive complaints
- Haemorrhoids
- Haemorrhoids
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Menopausal disorders
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nutrition (Infant)
- Nausea and vomiting
- Agitation in mania and psychotic disorders
- Schizophrenia
- Intraoperative mydriasis / prevention of miosis
- Stoma
- Arrhythmias
- Acute coronary syndrome
- Acute coronary syndrome
- Inotropic support
- IV catheter maintenance
- Cardiopulmonary resuscitation
- Hepatitis D
- Hypertension (severe / crisis)
- Heart failure
- Oedema
- Hypotension
- Tissue glue / suture support
- Diagnosis of Brugada syndrome
- Heparin induced thrombocytopenia
- HIV infection
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Stoma
- Smoking cessation
- Endometriosis
- Surgical diagnostic
- Ocular surgery
- Chronic Obstructive Pulmonary Disease (COPD)
- Growth failure - adults
- Growth failure - children
- Oesophagitis (inducing remission)
- Uterine fibroids
- Overactive bladder (adults)
- Retinal Vein Occlusion
- Hidradenitis suppurativa
- Alzheimers disease
- Alzheimers disease
- Osteoporosis
- Allergen immunotherapy
- Premedication
- Local anaesthesia
- Hereditary angiodema
- Hereditary angiodema
- Status epilepticus
- Type I Diabetes
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
23 January 2024
Not Set
This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing .
NICE have not yet provided a publication date but this drug will be considered by the APC within 90 days of NICE publication
Associated BNF Codes
08. Malignant Disease and Immunosuppression
08.02.04. Other immunomodulating drugs